Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Operating Margin (2018 - 2026)

Catalyst Pharmaceuticals filings provide 9 years of Operating Margin readings, the most recent being 49.02% for Q1 2026.

  • On a quarterly basis, Operating Margin rose 421.0% to 49.02% in Q1 2026 year-over-year; TTM through Mar 2026 was 44.83%, a 156.0% increase, with the full-year FY2025 number at 43.77%, up 409.0% from a year prior.
  • Operating Margin hit 49.02% in Q1 2026 for Catalyst Pharmaceuticals, up from 40.52% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 53.79% in Q2 2022 to a low of 36.21% in Q3 2023.
  • Median Operating Margin over the past 5 years was 44.21% (2024), compared with a mean of 38.74%.
  • Biggest five-year swings in Operating Margin: plummeted -8007bps in 2023 and later skyrocketed 7577bps in 2024.
  • Catalyst Pharmaceuticals' Operating Margin stood at 50.7% in 2022, then fell by -26bps to 37.71% in 2023, then increased by 18bps to 44.31% in 2024, then decreased by -9bps to 40.52% in 2025, then rose by 21bps to 49.02% in 2026.
  • The last three reported values for Operating Margin were 49.02% (Q1 2026), 40.52% (Q4 2025), and 44.66% (Q3 2025) per Business Quant data.